Guggenheim analyst Louise Chen reiterated a Buy rating and boosted her price target on Valeant Pharmaceuticals (NYSE: VRX) to $250.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Valeant Pharmaceuticals (VRX) PT Lifted to $271 at Cantor FitzgeraldApril 30, 2015 6:51 AM Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO TransitionApril 29, 2015 6:16 AM Valeant Pharmaceuticals Reports First Quarter 2015 Financial ResultsApril 29, 2015 6:00 AM Valeant Announces CFO Succession Plan And Additional Executive AppointmentApril 29, 2015 6:00 AM